Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin

Bibliography

• DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-95
   PubMed Web of Science ®Google Scholar
• Scheen AJ, Lefebvre PJ. Oral antidiabetic agents: a guide to selection. Drugs 1998;55:225-36
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Current management of coexisting obesity and type 2 diabetes. Drugs 2003;63:1165-84
   PubMed Web of Science ®Google Scholar
• Howlett H, Porte F, Allavoine T, The development of an oral antidiabetic combination tablet: design, evaluation and clinical benefits for patients with type 2 diabetes. Curr Med Res Opin 2003;19:218-25
   PubMed Web of Science ®Google Scholar
• Stumvoll M, Haring HU, Matthaei S. Metformin. Endocr Res 2007;32:39-57
   PubMed Web of Science ®Google Scholar
• Hundal RS, Inzucchi SE. Metformin: new understandings, new uses. Drugs 2003;63:1879-94
   PubMed Web of Science ®Google Scholar
• Setter SM, Iltz JL, Thams J, Campbell RK. Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy. Clin Ther 2003;25:2991-3026
   PubMed Web of Science ®Google Scholar
• Consoli A, Gomis R, Halimi S, Initiating oral glucose-lowering therapy with metformin in type 2 diabetic patients: an evidence-based strategy to reduce the burden of late-developing diabetes complications. Diabetes Metab 2004;30:509-16
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, Medical management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009;52:17-30
   PubMed Web of Science ®Google Scholar
• Scheen AJ, Lefebvre PJ. Antihyperglycaemic agents. Drug interactions of clinical importance. Drug Safety 1995;12:32-45
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokin 1996;30:359-71
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Drug interactions of clinical importance with antihyperglycaemic agents: an update. Drug Safety 2005;28:601-31
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-705
   PubMed Web of Science ®Google Scholar
• Ahren B. Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes. Expert Opin Emerg Drugs 2008;13:593-607
   PubMed Web of Science ®Google Scholar
• Lyseng-Williamson KA. Sitagliptin. Drugs 2007;67:587-97
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMEA): Januvia (sitagliptin) – European Public Assessment Report (EPAR) – Scientific Discussion; 2007. Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/januvia/H-722-en6.pdf [Last accessed 9 February 2010]
   Google Scholar
• Florentin M, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Sitagliptin in clinical practice: a new approach in the treatment of type 2 diabetes. Expert Opin Pharmacother 2008;9:1705-20
   PubMed Web of Science ®Google Scholar
• Dhillon S. Sitagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs 2010;70:489-512
   PubMed Web of Science ®Google Scholar
• Ahren B. Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin – diabetes control and potential adverse events. Best Pract Res Clin Endocrinol Metab 2009;23:487-98
   PubMed Web of Science ®Google Scholar
• Ahren B. Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin. Vasc Health Risk Manag 2008;4:383-94
   PubMedGoogle Scholar
• Scheen AJ, Radermecker RP. Addition of incretin therapy to metformin in type 2 diabetes. Lancet 2010;375:1410-12
   PubMed Web of Science ®Google Scholar
• Gagliardino JJ, Santoro S, Arellano S, Di Girolamo G. New treatments for type 2 diabetes mellitus: combined therapy with sitagliptin. Expert Opin Pharmacother 2008;9:1495-507
   PubMed Web of Science ®Google Scholar
• Gallwitz B. Sitagliptin with metformin: profile of a combination for the treatment of type 2 diabetes. Drugs Today (Barc) 2007;43:681-9
   PubMed Web of Science ®Google Scholar
• Reynolds JK, Neumiller JJ, Campbell RK. Janumet: a combination product suitable for use in patients with Type 2 diabetes. Expert Opin Invest Drugs 2008;17:1559-65
   PubMed Web of Science ®Google Scholar
• Green J, Feinglos M. New combination treatments in the management of diabetes: focus on sitagliptin-metformin. Vasc Health Risk Manag 2008;4:743-51
   PubMedGoogle Scholar
• EMEA Janumet Assessment Report. Available from: www.ema.europa.eu/humandocs/PDFs/EPAR/janumet/H-861-en6.pdf
   Google Scholar
• Halimi S, Schweizer A, Minic B, Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet. Vasc Health Risk Manag 2008;4:481-92
   PubMedGoogle Scholar
• He YL, Paladini S, Sabia H, Bioequivalence of vildagliptin/metformin fixed-dose combination tablets and a free combination of vildagliptin and metformin in healthy subjects. Int J Clin Pharmacol Ther 2008;46:259-67
   PubMed Web of Science ®Google Scholar
• Sambol NC, Brookes LG, Chiang J, Food intake and dosage level, but not tablet vs solution dosage form, affect the absorption of metformin HCl in man. Br J Clin Pharmacol 1996;42:510-12
   Google Scholar
• Timmins P, Donahue S, Meeker J, Marathe P. Steady-state pharmacokinetics of a novel extended-release metformin formulation. Clin Pharmacokinet 2005;44:721-9
   PubMed Web of Science ®Google Scholar
• Cullen E, Liao J, Lukacsko P, Pharmacokinetics and dose proportionality of extended-release metformin following administration of 1000, 1500, 2000 and 2500 mg in healthy volunteers. Biopharm Drug Dispos 2004;25:261-3
   PubMed Web of Science ®Google Scholar
• Schwartz S, Fonseca V, Berner B, Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes. Diabetes Care 2006;29:759-64
   PubMed Web of Science ®Google Scholar
• Choi MK, Song IS. Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet 2008;23:243-53
   PubMed Web of Science ®Google Scholar
• Pacanowski MA, Hopley CW, Aquilante CL. Interindividual variability in oral antidiabetic drug disposition and response: the role of drug transporter polymorphisms. Expert Opin Drug Metab Toxicol 2008;4:529-44
   PubMed Web of Science ®Google Scholar
• Wang DS, Jonker JW, Kato Y, Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther 2002;302:510-15
   PubMed Web of Science ®Google Scholar
• Kimura N, Masuda S, Tanihara Y, Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet 2005;20:379-86
   PubMedGoogle Scholar
• Atanasova I, Bozhinova K, Todorova D, Terziivanov D. Pharmacokinetics and comparative bioavailability of two metformin formulations after single-dose administration in healthy subjects. Clin Drug Investig 2003;23:743-9
   PubMed Web of Science ®Google Scholar
• Hermann LS, Schersten B, Melander A. Antihyperglycaemic efficacy, response prediction and dose-response relations of treatment with metformin and sulphonylurea, alone and in primary combination. Diabet Med 1994;11:953-60
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995;333:541-9
   PubMed Web of Science ®Google Scholar
• Takane H, Shikata E, Otsubo K, Polymorphism in human organic cation transporters and metformin action. Pharmacogenomics 2008;9:415-22
   PubMed Web of Science ®Google Scholar
• Shikata E, Yamamoto R, Takane H, Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin. J Hum Genet 2007;52:117-22
   PubMed Web of Science ®Google Scholar
• Shu Y, Brown C, Castro RA, Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther 2008;83:273-80
   PubMed Web of Science ®Google Scholar
• Shu Y, Sheardown SA, Brown C, Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 2007;117:1422-31
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab 2010;12:648-58
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug–drug interactions. Clin Pharmacokinet 2010;49:573-88
   PubMed Web of Science ®Google Scholar
• Vincent SH, Reed JR, Bergman AJ, Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans. Drug Metab Dispos 2007;35:533-8
   PubMed Web of Science ®Google Scholar
• Bergman AJ, Stevens C, Zhou Y, Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther 2006;28:55-72
   PubMed Web of Science ®Google Scholar
• Herman GA, Bergman A, Liu F, Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol 2006;46:876-86
   PubMed Web of Science ®Google Scholar
• Herman GA, Stevens C, Van Dyck K, Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 2005;78:675-88
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Current management strategies for coexisting diabetes mellitus and obesity. Drugs 2003;63:1165-84
   PubMed Web of Science ®Google Scholar
• Herman GA, Bergman A, Stevens C, Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006;91:4612-19
   PubMed Web of Science ®Google Scholar
• Herman GA, Bergman A, Yi B, Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes. Curr Med Res Opin 2006;22:1939-47
   PubMed Web of Science ®Google Scholar
• Bergman AJ, Cote J, Yi B, Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care 2007;30:1862-4
   PubMed Web of Science ®Google Scholar
• Chan JC, Scott R, Arjona Ferreira JC, Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. Diabetes Obes Metab 2008;10:545-55
   PubMed Web of Science ®Google Scholar
• Migoya EM, Stevens CH, Bergman AJ, Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin. Can J Clin Pharmacol 2009;16:e165-70
   PubMedGoogle Scholar
• Williams-Herman D, Engel SS, Round E, Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord 2010;10:7
   PubMed Web of Science ®Google Scholar
• Mannucci E, Ognibene A, Cremasco F, Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care 2001;24:489-94
   PubMed Web of Science ®Google Scholar
• Mannucci E, Tesi F, Bardini G, Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without Type 2 diabetes. Diabetes Nutr Metab 2004;17:336-42
   PubMedGoogle Scholar
• Migoya EM, Miller J, Larson P, Sitagliptin, a selective DPP-4 inhibitor, and metformin have complementary effects to increase active GLP-1 concentrations [abstract]. Diabetes 2007;56(Suppl 1):A74
   Google Scholar
• Hinke SA, Kuhn-Wache K, Hoffmann T, Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1. Biochem Biophys Res Commun 2002;291:1302-8
   PubMed Web of Science ®Google Scholar
• Brazg R, Xu L, Dalla Man C, Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. Diabetes Obes Metab 2007;9:186-93
   PubMed Web of Science ®Google Scholar
• Arnolds S, Dellweg S, Clair J, Further improvement in postprandial glucose control when adding exenatide (EXE) or sitagliptin (SITA) to combination therapy with insulin glargine (GLAR) and metformin (MET) – a proof-of-concept study. Diabetes Care 2010;33:1509-15
   PubMed Web of Science ®Google Scholar
• Charbonnel B, Karasik A, Liu J, Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006;29:2638-43
   PubMed Web of Science ®Google Scholar
• Raz I, Chen Y, Wu M, Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin 2008;24:537-50
   PubMed Web of Science ®Google Scholar
• Scott R, Loeys T, Davies MJ, Engel SS. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2008;10:959-69
   PubMed Web of Science ®Google Scholar
• Nauck MA, Meininger G, Sheng D, Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007;9:194-205
   PubMed Web of Science ®Google Scholar
• Seck T, Nauck MA, Sheng D, Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract 2010;64:562-76
   PubMed Web of Science ®Google Scholar
• Bergenstal RM, Wysham C, Macconell L, Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010. [Epub ahead of print]
   Google Scholar
• Pratley RE, Nauck M, Bailey T, ; for the 1860-LIRA-DPP-4 Study Group. Liraglutide versus sitagliptin in patients with type 2 diabetes inadequately controlled on metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010;375:1447-56
   PubMed Web of Science ®Google Scholar
• Schwarz B, Gouveia M, Chen J, Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy. Diabetes Obes Metab 2008;10(Suppl 1):43-55
   PubMedGoogle Scholar
• Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Pharmacologic treatment of diabetes. Can J Diabetes 2008;32(Suppl 1):S53-61
   Google Scholar
• Sibal L, Home PD. Management of type 2 diabetes: NICE guidelines. Clin Med 2009;9:353-7
   PubMed Web of Science ®Google Scholar
• Goldstein BJ, Feinglos MN, Lunceford JK, ; Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007;30:1979-87
   PubMed Web of Science ®Google Scholar
• Williams-Herman D, Johnson J, Teng R, Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Curr Med Res Opin 2009;25:569-83
   PubMed Web of Science ®Google Scholar
• Williams-Herman D, Johnson J, Teng R, Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes Obes Metab 2010;12:442-51
   PubMed Web of Science ®Google Scholar
• Holstein A, Stumvoll M. Contraindications can damage your health – is metformin a case in point? Diabetologia 2005;48:2454-9
   PubMed Web of Science ®Google Scholar
• Engel SS, Williams-Herman DE, Golm GT, Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. Int J Clin Pract 2010;64:984-90
   PubMed Web of Science ®Google Scholar